Tg(PDGFB-LRRK2*G2019S)340Djmo
Transgene Detail
|
Symbol: |
Tg(PDGFB-LRRK2*G2019S)340Djmo |
Name: |
transgene insertion 340, Darren Moore |
MGI ID: |
MGI:4950671 |
Synonyms: |
G2019S-LRRK2 |
Transgene: |
Tg(PDGFB-LRRK2*G2019S)340Djmo Location: unknown
|
Alliance: |
Tg(PDGFB-LRRK2*G2019S)340Djmo page
|
|
Progressive loss of substantia nigra dopaminergic neurons in Tg(PDGFB-LRRK2*G2019S)340Djmo/0 transgenic mice
Show the 6 phenotype image(s) involving this allele.
|
|
|
|
Transgene Type: |
|
Transgenic (Humanized sequence, Inserted expressed sequence) |
Mutation: |
|
Insertion
|
|
|
Tg(PDGFB-LRRK2*G2019S)340Djmo expresses
1 gene
Transgene expresses:
Organism |
Expressed Gene |
Homolog in Mouse |
Note |
human |
LRRK2 (120892) |
|
|
|
|
|
Mutation details: The G2019S-LRRK2 transgene was designed with a minimal cytomegalovirus (CMV) enhancer and human platelet derived growth factor, B polypeptide (PDGFB) promoter/enhancer elements driving expression of a full length human leucine-rich repeat kinase 2 (LRRK2) cDNA. LRRK2 cDNA was modified by targeted mutation of the LRRK2 locus to harbor the LRRK2*G2019S mutation associated with autosomal dominant, late-onset Parkinson's disease. Line 340 was generated.
(J:171645)
|
|
Schematic of the Tg(PDGFB-LRRK2*G2019S)340Djmo or Tg(PDGFB-LRRK2*R1441C)574Djmo transgene |
|
|
View phenotypes and curated references for all genotypes (concatenated display).
|
|
Mouse strains and cell lines
available from the International Mouse Strain Resource
(IMSR) |
Carrying this Mutation: |
Mouse Strains: 1 strain available
Cell Lines: 0 lines available
|
|
Original: |
J:171645 Ramonet D, et al., Dopaminergic Neuronal Loss, Reduced Neurite Complexity and Autophagic Abnormalities in Transgenic Mice Expressing G2019S Mutant LRRK2. PLoS One. 2011;6(4):e18568 |
All: |
7 reference(s) |
|